Actively Recruiting
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
Led by Peking University First Hospital · Updated on 2025-12-30
178
Participants Needed
3
Research Sites
387 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an ambispective cohort observational study to analyze the efficacy of adjuvant radioimmunotherapy (radiotherapy and immunotherapy) compared with adjuvant chemotherapy in patients with the upper urinary tract urothelial carcinoma with high-risk factors (postoperative pathology suggestive of pT2 and above, N+, G3/high-grade and multiple tumors, positive cut margins). A subgroup analysis was performed to obtain the population of patients who might benefit from different treatment approaches. Patients with high risk factors for postoperative recurrence or metastasis will be treated with relevant adjuvant therapy, which in turn will benefit patients.
CONDITIONS
Official Title
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of upper urinary tract urothelial carcinoma (UTUC)
- High-risk UTUC including stage pT2 or higher, lymph node positive, tumor grade 3, multiple tumors, or positive surgical margins
- 18 years of age or older
You will not qualify if you...
- Presence of distant metastases at surgery or incomplete tumor removal (non-R0 resection)
- Prior pelvic or abdominal radiotherapy, history of inflammatory bowel disease, or previous systemic chemotherapy
- Pregnant or breastfeeding women, or women of childbearing potential not using reliable contraception
- History of other malignant tumors except certain skin cancers and cervical cancer cured over 5 years ago
- Weight loss over 10% in the last 6 months
- Bleeding disorders or active infections
- Poor health condition unable to tolerate treatment
- Unable to provide informed consent due to psychological, family, social, or other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Departmeng of Urology, Peking University First Hospital
Beijing, China
Actively Recruiting
2
Department of Medical Oncology, Peking University First Hospital
Beijing, China
Actively Recruiting
3
Department of Radiotherapy Oncology, Peking University First Hospital
Beijing, China
Actively Recruiting
Research Team
X
Xuesong Li, M.D.
CONTACT
C
Chunru Xu, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here